How to Get Generic Semaglutide Prescribed Online in Canada (2026)

Novo Nordisk's regulatory exclusivity for semaglutide ended on January 4, 2026 in Canada, which opened the door for generic manufacturers (CMA). As of late December 2025, the CMA reported that Health Canada had nine active applications from companies seeking to sell generic semaglutide. Those applications have started converting into authorized products.

Two are now on the record:

• Apo-Semaglutide Injection (Apotex) received a Health Canada date of authorization of 2026-05-01 and was commercially launched on May 14, 2026, described by Apotex as a generic equivalent of Ozempic (Apotex/PR Newswire).
• SEVMIA (Apotex) received a Health Canada date of authorization of 2026-06-29 and was announced by Apotex the following day, on June 30, 2026, as the first Health Canada approval for a generic equivalent of Wegovy (SEVMIA Product Monograph; Apotex/PR Newswire).

One distinction trips people up: "generic semaglutide" is not one product. The two carry different authorized indications, pen strengths, and dose ranges, so which one a prescriber writes for depends on what is being managed — and one is not interchangeable with the other.

Authorization is also not shelf stock. Supply rolls out unevenly across wholesalers, chains, and provinces, so "where will this be filled?" is worth answering before the prescription is written.

Eligibility is a prescriber's clinical judgment, not something you can self-assess. Here is what each product is authorized for, in Health Canada's own words.

Apo-Semaglutide Injection — from the Health Canada authorized product monograph:

"APO-SEMAGLUTIDE INJECTION (semaglutide injection) is indicated for the once-weekly treatment of adult patients with type 2 diabetes to improve glycemic control, in combination with: diet and exercise in patients for whom metformin is inappropriate due to contraindication or intolerance."

The monograph lists further combination scenarios involving metformin, sulfonylureas, SGLT2 inhibitors, and basal insulin. It is an adult indication; the monograph does not authorize pediatric use.

SEVMIA is authorized as a generic equivalent of Wegovy, quoted in full from the Health Canada authorized product monograph:

"SEVMIA™ (semaglutide injection) is indicated:

• as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in:
  • Adult patients with an initial body mass index (BMI) of
    • 30 kg/m2 or greater (obesity), or
    • 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea.
  • Pediatric patients aged 12 to less than 18 years:
    • with an initial BMI at the 95th percentile or greater for age and sex (obesity; see Table 1), and
    • a body weight above 60 kg (132 lbs), and
    • an inadequate response to reduced calorie diet and physical activity alone.
• to reduce the risk of non-fatal myocardial infarction in adults with established cardiovascular disease and BMI equal to or greater than 27 kg/m2."

Wegovy's own monograph sets out the same criteria and the same myocardial infarction indication, and adds one SEVMIA does not carry: non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) (Wegovy Product Monograph, Section 1 Indications, date of authorization December 10, 2025).

On off-label prescribing. The CMA notes that Ozempic is not approved for weight loss in Canada and that a doctor may prescribe it off-label — meaning a drug approved for one condition is prescribed for another (CMA). The same distinction applies to its generic equivalent, which carries the type 2 diabetes indication only. Off-label prescribing is lawful in Canada and is a decision between a patient and their prescriber; some prescribers will consider it, others decline. We take no position either way.

There are four realistic routes, and they trade off differently.

Your family doctor. Strongest for continuity: they hold your history, can order bloodwork, and manage dose changes over time. Slowest to start.

A walk-in clinic. Faster access, but the clinician is meeting you cold and may not have your records. Whether they'll start something long-term at a first visit or send you elsewhere varies by clinic and by clinician — ask before you sit down, rather than assume either way.

Telehealth. Virtual platforms are built for asynchronous intake and can be convenient if you don't have a regular provider. The tradeoff is continuity: confirm who handles follow-up, dose adjustments, and questions after the first prescription, and whether fees recur. Providers differ substantially on all of it.

Felix is one such platform, and one we earn a commission from. Its intake is online with no video visit, the initial assessment fee is $0.00, and if a practitioner prescribes, apo-semaglutide is $149.00/month at the 0.25, 0.5 and 1.0 mg pen strengths and more at the higher maintenance strengths. Apo-Semaglutide is approved by Health Canada for type 2 diabetes; prescribing it for weight management is off-label, at the prescriber's clinical judgment. Felix does not dispense SEVMIA, its application is a weight-management intake, and approval is not guaranteed. It also doesn't operate in every province, so confirm yours is served before you pay.

Compare all telehealth providers on our hub rather than taking any single provider's word for how its service works.

A pharmacist. This one depends heavily on where you live. The Canadian Pharmacists Association's national chart shows that Alberta is the only jurisdiction where pharmacists can prescribe independently for any Schedule I drug; every other province and territory is marked as not implemented for that authority. Pharmacists can renew or extend an existing prescription in every jurisdiction except Nunavut, and can adapt a dose, formulation, or regimen everywhere except the Northwest Territories and Nunavut (CPhA, Prescribing Authority of Pharmacists Across Canada). The minor-ailment lists that underpin pharmacist prescribing elsewhere cover things like dermatological, gastrointestinal, and respiratory conditions — they do not cover starting semaglutide.

So: outside Alberta, a pharmacist is realistically the person who continues or adapts your therapy, not the one who starts it. In Alberta the scope permission itself is narrower than "any pharmacist": CPhA's chart footnotes it to pharmacists who hold Additional Prescribing Authorization (APA), a credential on top of the base licence that not every pharmacist in the province pursues. Even for one who holds it, whether they write for a particular drug is their own clinical judgment and practice setting, exactly as it is for any prescriber. Ask rather than assume.

1. Intake. You complete a structured medical questionnaire — health history, current medications, allergies, relevant measurements, and what you're seeking care for. Answer it accurately; this is the clinical record the decision rests on.
2. Practitioner review. A licensed practitioner reviews your intake. This is where the synchronous vs asynchronous distinction matters. Asynchronous means the practitioner reviews your written submission on their own schedule and you may never speak live. Synchronous means a real-time video or phone consultation. Neither is inherently better, but if you want to actually talk to someone, confirm which model a service uses before you pay.
3. The decision. The practitioner may approve, decline, request more information, ask for bloodwork, or recommend something else entirely. A prescription is not a guaranteed outcome of paying an intake fee — that is worth understanding up front.
4. Prescription and fill. If a prescription is issued, it's transmitted to a pharmacy: your local one, or a partner/mail-order pharmacy. With generics specifically, ask whether the receiving pharmacy has the product in stock, because this is where availability gaps show up.
5. Follow-up. Semaglutide is dosed on an escalating schedule, so follow-up is part of the process, not an optional extra. Confirm who owns it.

We deliberately don't publish "prescription in X hours" figures. Those are provider marketing claims, and we haven't verified any of them.

Once you hold a prescription, you can generally fill it at any licensed Canadian pharmacy that stocks the product — chains, independents, or mail-order. Cash prices are not standardized, and can differ meaningfully across the street, let alone across provinces.

At the 1 verified Canadian pharmacy currently listing it, generic semaglutide runs $88–$99 per pen as of July 18, 2026.

For the province-level picture, see our generic Ozempic cost guide for Canada or the breakdowns for Ontario, British Columbia, Quebec, and Alberta. For the weight-management generic, see the Sevmia cost guide. Live listings are on the Apo-Semaglutide drug page; our methodology page explains how we verify prices.

You are far from alone, and not having one does not disqualify you. An estimated 5.9 million adults in Canada do not have a family doctor, nurse practitioner, or primary care team they see regularly, according to the OurCare survey led by Dr. Tara Kiran at Unity Health Toronto in partnership with the Canadian Medical Association (CMA, December 8, 2025).

Practically, that pushes more people toward the walk-in and telehealth routes — which makes follow-up more important, not less. Dose escalation, side-effect questions, and renewals all need somewhere to land. Get a clear answer to "who do I contact in six weeks?" before starting. If a service can't answer plainly, that's useful information.

For the fuller picture — walk-in clinics, telehealth, what pharmacists can and can't prescribe by province, and what to plan for at renewal — see our guide to getting a GLP-1 prescription without a family doctor.

Any website offering semaglutide without a prescription is a red flag. The CMA puts it directly: if a website says you can get a GLP-1 drug without a prescription, that's a major red flag (CMA).

Health Canada lists warning signs that an online pharmacy may be fraudulent, including that it "Does not require a valid prescription," offers drugs at very low discounted prices, does not provide a bricks-and-mortar business address, or is located outside of Canada. Conversely, a legitimate online pharmacy "Requires a valid prescription from a physician or other health practitioner licensed to practice in Canada," is licensed by a provincial or territorial pharmacy regulatory authority, and provides a street address in Canada (Health Canada, Choosing a safe online pharmacy).

Health Canada also warns that if you buy from a fraudulent online pharmacy, "You may end up with a drug that contains wrong or harmful ingredients, or no medicinal ingredients at all," and notes that injectable medications often require proper refrigeration that fraudulent sellers may not maintain. On importing: "You cannot legally import a prescription drug unless you are a practitioner, a drug manufacturer, a wholesale druggist, a registered pharmacist, or a resident of a foreign country while a visitor in Canada."

A specific caution for generics: because generic semaglutide is new and supply is still ramping, scarcity is exactly the condition that unauthorized sellers exploit. A site that has stock when licensed pharmacies don't is a warning sign, not a find. You can verify whether a Canadian-addressed pharmacy is licensed by checking with that province's pharmacy regulatory authority.